Metabolic health issues have attracted growing public attention nowadays, and hyperuricemia has evolved into a prevalent metabolic disorder. Statistics reveal that the total number of people living with hyperuricemia and gout worldwide has exceeded 1.1 billion, with over 18% of the population affected in China. The market demand for safe and sustainable uric acid management solutions keeps rising steadily. Developed jointly by Synbio Tech and South China University of Technology, Lactobacillus plantarum FS4722 adopts a multi-target metabolic regulation mechanism, offering a novel probiotic-based solution for people with elevated uric acid levels.
This functional probiotic strain was screened from the fermentation ecosystem of traditional Chinese pickles. Analyses via metagenomics and metabolomics conducted by the research team confirmed that strain FS4722 carries nucleoside hydrolase genes RiHA, RiHB and RiHC, endowing it with distinctive nucleoside degradation capacity. It breaks down nucleoside substrates such as inosine and guanosine within the intestine, thereby curbing purine absorption at the metabolic source.
The efficacy of the strain has been verified through multi-layered scientific trials. In animal model experiments using hyperuricemic mice, therapeutic effects were observed in the FS4722 intervention group starting on Day 4, with markedly improved outcomes by Day 7. Mechanism research demonstrates that the strain downregulates the expression of intestinal transporters and diminishes intestinal absorption of purines. Human trial data showed that after six consecutive weeks of supplementation with FS4722, subjects with high uric acid achieved an average 9.3% reduction in serum uric acid, with no adverse reactions including abnormal organ function recorded throughout the trial.
FS4722 exerts synergistic regulation on uric acid metabolism via a three-tier regulatory system:
Inhibit uric acid synthesis: The strain secretes organic acids to lower intestinal pH and suppress the activity of purine nucleoside phosphorylase. Its bacterial proteins bind key catalytic enzymes to reduce endogenous uric acid production.
Boost uric acid excretion: It modulates transporter genes associated with the gut-kidney axis, cuts down uric acid reabsorption in renal tubules and facilitates uric acid discharge from the body.
Optimize intestinal microecology: It regulates the production of short-chain fatty acids and reshapes the intestinal flora composition to indirectly assist uric acid metabolism. Safety assessments confirm that the strain causes no damage to renal or intestinal tissues, boasting superior safety profiles compared with conventional intervention approaches.
Proprietary supporting technologies have been developed to support the practical application of the strain. The SYNTEK® enhancement integration technology combined with the SINPACK® viability preservation process maintains abundant viable bacteria throughout a 24-month shelf life. Formulated blends pairing the strain with mulberry leaf extract and other ingredients deliver synergistic benefits. These technologies have obtained invention patents in China, the United States and multiple other regions. Lactobacillus plantarum FS4722 has been granted a Chinese invention patent, and it also exhibits potential research value in regulating body weight and blood lipid metabolism beyond uric acid management.
Industry analysts note that unlike traditional intervention methods, functional probiotics target intestinal metabolism, pioneering a new segment in metabolic health. The development and commercialization of Lactobacillus plantarum FS4722 proves that probiotics are not limited to intestinal care; they hold vast prospects in metabolic health and provide valuable references for product innovation within the wellness industry.
Disclaimer: All findings are derived from animal experiments and human trial data. This strain is a dietary probiotic raw material and cannot replace medicines for the treatment of gout, hyperuricemia or other illnesses.
Tel:029-68082905
Mobile:+8618092051671
E-mail: billy@zebragopharma.com
Skype: beckyshi2010
Whatsapp: +8618092051671